Dengvaxia has faced several controversies, primarily due to its safety profile in dengue-naive individuals. Following its introduction in the Philippines, concerns arose over the administration of the vaccine to individuals without prior dengue infection, leading to an increased incidence of severe dengue cases. This resulted in a temporary suspension of the vaccination program and widespread public concern.
